A61B5/4244

BREATH ANALYZER DEVICES AND BREATH TEST METHODS
20220039690 · 2022-02-10 ·

The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, the bacterium H. pylori in a subjects digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.

MAGNETIC RESONANCE FINGERPRINTING METHOD FOR RECORDINGS WITH A CONTRAST AGENT
20210389402 · 2021-12-16 · ·

The present disclosure relates to the technical field of magnetic resonance tomography. The present disclosure relates to a method, a system and a computer program product for determining different states of a contrast agent in different types of tissue in a magnetic resonance fingerprinting method.

Method and apparatus for providing a quantitative volumetric map of an organ or an assessment of organ health

A method of providing a quantitative volumetric assessment of organ health or a quantitative map of an organ. The method comprises obtaining a volumetric map of organ health comprising information defining a state of tissue health across at least part of an organ, receiving an input defining at least one organ section, determining an assessment organ volume based at least partly on the at least one defined organ section, calculating an organ-viability measure for the assessment organ volume based at least partly on information within the volumetric map defining the state of tissue health across the organ volume, and outputting an indication of the organ-viability measure.

NEUROMODULATION TO TARGET GLUCOSE TRANSPORTER AND/OR INCRETIN PATHWAYS

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

ALGORITHM FOR THE IDENTIFICATION AND PHENOTYPING OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS

System and methods for diagnosing nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in patients are disclosed. The system can comprise one or more processors and one or more computer-readable non-transitory storage media coupled to the one or more of processors including instructions operable when executed by one or more of the processor. The system can be configured to select at least one patient with a risk indicator using an electronic health record (EHR) database, determine that the at least one patient fails to meet exclusion criteria, and display the at least one patient in response to the determination. The risk indicator can be associated with NAFLD and/or NASH. Methods for diagnosing NAFLD/NASH in patients are disclosed are also provided.

System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography

The present disclosure relates to a system and method for non-invasively determining NAFLD activity scores (NAS) in patients using mechanical properties determined through magnetic resonance elastography (MRE) imaging. The non-invasively determined NAS score is then used to diagnose NFALD and NASH patients.

Radio frequency applicator for a thermoacoustic imaging system

A radio frequency applicator for a thermoacoustic imaging system is disclosed. The applicator includes, a waveguide with an internal radio frequency source, wherein the waveguide has an opening, an electromagnetic matching layer coupled to the waveguide and proximate to the opening, and an acoustic absorbing layer that is coupled to the matching layer.

Forecast of MRI images by means of a forecast model trained by supervised learning

The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.

Ensemble Machine Learning Model Architecture for Lesion Detection

A lesion detection ensemble machine learning model architecture comprising a plurality of trained machine learning (ML) computer models is provided. A first decoder of a lesion detection ML model processes a medical image input to generate a first lesion mapping prediction. A second decoder of the lesion detection ML model processes the medical image input to generate a second lesion mapping prediction. Combinational logic combines the first and second lesion mapping predictions to generate a combined prediction. Final lesion mapping output logic generates a final lesion prediction based on the combined lesion mapping prediction. The final lesion mapping output logic outputs the final lesion prediction for further downstream computing operations. The first decoder is trained with a first loss function that is configured to counterbalance a training of the second decoder that is trained using a second loss function different from the first loss function.

Imaging apparatus

An imaging apparatus that is easily moved between locations protects an imaging element in motion and provides a first arm member and a proximate movable second arm member. A lighting-imaging element is movably positionable proximate an arm mechanism and also proximate a rear-side location of a wheeled platform relative to a traveling direction thereby preventing damage. The first and second arm are relatively surrounded with a sub-arm and lighting-imaging element, thereby preventing further unintended movement. Accordingly, an elongating (separation) of the first and second arm members are prevented.